Our broad objective is to quantify surgeon performance, build automated assessments grounded in patient-centered outcomes, and develop quality assurance programs to improve training for surgeons.
   

This clinical trial is for adult participants who have an advanced or metastatic solid tumor and have received prior standard therapy.
   

The purpose of this research study is to compare any good and bad effects of giving ipilimumab, nivolumab, and GM-CSF (Sargramostim) at the same time compared to just ipilimumab and nivolumab together for advanced melanoma. It would also like to find out what effects, good and bad, this combination of drugs may have on the cancer. 

This clinical trial is for men and women with advanced cancer or cancer that has spread to other parts of the body, and have either not tolerated the standard therapy, or there is no standard therapy available.

The purpose of this study is to test the safety of an investigational (experimental) drug, TAC-001, to see what effects it has on the cancer. Investigational means that it is not yet approved by the U.S. Food and Drug Administration (FDA). 

The purpose of this study is to determine the effectiveness of a new ultrasound technique to detect cancer and/or other abnormalities in lymph nodes, small bean-shaped structures that are part of the body's immune system. Participants in this study will have at least one lymph node that may be larger than normal. 

The purpose of this study is to find out what effects an immunotherapy drug, called pembrolizumab, combined with a radioactive drug, called lutetium Lu 177 dotatate (Lutathera®) have on Merkel cell carcinoma.

The purpose of this study is to test the safety and effectiveness of the experimental combination of tazemetostat with chimeric antigen receptor t-cell (CAR T) cell therapy, and see what effects it has on lymphoma. An additional purpose of this study is to understand what side effects people may have when they receive both drugs together.

This clinical trial is for men and women with newly diagnosed Acute Myeloid Lymphoma (AML) who are not eligible for intensive chemotherapy.
   
The purpose of this study is to evaluate the safety and effectiveness of the addition of an experimental drug, magrolimab, in combination with venetoclax and azacitidine compared to venetoclax and azacitidine alone.
   
Experimental means that magrolimab has not yet been approved by the U.S. Food and Drug Administration (FDA).
   

This study is being conducted to learn more about the effects and safety of the investigational/experimental study drug MGL-3196 (resmetirom) and compare the study drug with placebo in men or women who have been diagnosed with Non-Alcoholic Steatohepatitis (NASH). 
   
An investigational/experimental study drug is one that has not been approved by the Food and Drug Administration (FDA). 
   

This clinical trial is for adult participants who have myelofibrosis for which standard therapy has proven ineffective, or for those who cannot tolerate the standard therapy or are not able to receive the standard therapy.